Buy & Sell Marriott International Inc (MAR) – Marriott International Inc Price Today
Aura AI Summary
Key Stats
- $102.00BMarket Cap
- Consumer CyclicalSector
- -8.31%3M Drawdown
- $118.95BEnterprise Value
- 0.75%Dividend Yield
- 65% Buy | 35% SellTrading Activity
- 156 daysTypical Hold Time
Marriott International Inc (MAR) is currently valued at a market capitalization of $102.00B, with an enterprise value of $118.95B. Over the past 52 weeks, Marriott International Inc has traded between a low of $255.35 and a high of $402.54, highlighting its annual price range. Over the past three months, Marriott International Inc has recorded a drawdown of -8.31%, reflecting recent price volatility. Marriott International Inc offers a dividend yield of 0.75%, with the most recent dividend of $0.73 paid on 22 May 26. On average, investors hold Marriott International Inc for approximately 156 days, indicating typical investor behavior on the platform.
About Marriott International Inc
Marriott International Inc. of Maryland is a worldwide operator and franchisor of hotels. The Company franchises lodging facilities and vacation timesharing resorts under various brand names. Marriott also provides services to home and condominium owner associations for projects associated with several of its brands.
Most Recent News
Man Group discloses 1.57% stake in Senior Plc via derivatives as of June 23, 2026
Man Group PLC filed a Form 8.3 disclosure revealing it holds a 1.57% interest in Senior Plc, primarily through cash-settled derivatives, totaling 6,613,314 securities as of June 23, 2026. This disclosure is part of regulatory requirements under the T...

Bunzl Canada’s Cleaning & Hygiene division earns top Diamond status from Ontario Education Collaborative Marketplace.
Bunzl Canada's Cleaning & Hygiene division has achieved the Diamond status, the highest recognition from the Ontario Education Collaborative Marketplace (OECM) supplier program for 2025. This honor highlights Bunzl's consistent excellence in service,...

Biotech M&A heats up with Legend Biotech as top takeover target due to strong revenue and strategic fit.
Biotech mergers and acquisitions are gaining momentum as Big Pharma seeks to offset upcoming patent losses. Among potential targets, Legend Biotech stands out for its revenue-generating CAR-T therapy Carvykti, co-developed with Johnson & Johnson, sho...
